Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Sunday 05.04.2020 at 10:00 AM CEST
Settings

Settings

1. WO1996003423 - HAPTEN-MARKED PEPTIDES

Publication Number WO/1996/003423
Publication Date 08.02.1996
International Application No. PCT/EP1995/002921
International Filing Date 24.07.1995
IPC
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C07K 14/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
G01N 33/532 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
G01N 33/533 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
533with fluorescent label
G01N 33/543 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2740/16122
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/24222
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
24011Flaviviridae
24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
G01N 33/532
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
G01N 33/533
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
533with fluorescent label
G01N 33/54306
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
54306Solid-phase reaction mechanisms
Applicants
  • BOEHRINGER MANNHEIM GMBH [DE/DE]; Sandhofer Strasse 112-132 D-68305 Mannheim, DE (AllExceptUS)
  • HÖSS, Eva [DE/DE]; DE (UsOnly)
  • SEIDEL, Christoph [DE/DE]; DE (UsOnly)
  • WIENHUES, Ursula-Henrike [DE/DE]; DE (UsOnly)
  • FAATZ, Elke [DE/DE]; DE (UsOnly)
  • SCHMITT, Urban [DE/DE]; DE (UsOnly)
Inventors
  • HÖSS, Eva; DE
  • SEIDEL, Christoph; DE
  • WIENHUES, Ursula-Henrike; DE
  • FAATZ, Elke; DE
  • SCHMITT, Urban; DE
Agents
  • WEICKMANN, H. ; Kopernikusstrasse 9 D-81679 München, DE
Priority Data
P 44 26 276.025.07.1994DE
P 44 30 973.231.08.1994DE
Publication Language German (DE)
Filing Language German (DE)
Designated States
Title
(DE) HAPTEN-MARKIERTE PEPTIDE
(EN) HAPTEN-MARKED PEPTIDES
(FR) PEPTIDES MARQUES PAR UN HAPTENE
Abstract
(DE)
Die Erfindung betrifft ein Verfahren zur Herstellung von Hapten-markierten Peptiden, dadurch gekennzeichnet, daß man (a) ein Peptid mit der gewünschten Aminosäuresequenz an einer Festphase aus Aminosäurederivaten synthetisiert, deren reaktive Seitengruppen durch Schutzgruppen blockiert sind, wobei die Schutzgruppen an primären Aminoseitengruppen derart ausgewählt werden, daß sie gegebenenfalls selektiv abspaltbar sind, (b) eine Abspaltung von Schutzgruppen durchführt, wobei mindestens eine freie primäre Aminogruppe entsteht, (c) ein Hapten-Aktivesterderivat an die mindestens eine freie primäre Aminogruppe des Peptids koppelt, und (d) gegebenenfalls eine Abspaltung von noch verbleibenden Schutzgruppen durchführt, wobei das Hapten ausgewählt wird aus der Gruppe bestehend aus Sterinen, Gallensäuren, Sexualhormonen, Corticoiden, Cardenoliden, Cardenolid-Glycosiden, Bufadienoliden, Steroid-Sapogeninen und Steroidalkaloiden.
(EN)
The invention concerns a method of producing hapten-marked peptides, characterized by the fact that (a) a peptide with the desired amino acid sequence is synthesised on a solid phase of amino acid derivatives whose reactive side groups are blocked by protective groups selected on primary amino side groups to ensure that they can be selectively split off; (b) protective groups are split off, producing at least one free primary amino group; (c) a hapten-active ester derivative is coupled to at least one free primary amino group of the peptide; and (d) where appropriate, remaining protective groups are split off. The hapten is selected from a group comprising sterines, gallic acids, sex hormones, corticoids, cardenolids, cardenolid-glycosides, bufadienolides, steroid-sapogenins and steroid alkaloids.
(FR)
L'invention concerne un procédé pour produire des peptides marqués par un haptène, caractérisé en ce que: a) un peptide avec la séquence aminoacide désirée est synthétisé sur une phase solide de dérivés aminoacides dont les groupes latéraux réactifs sont bloqués par des groupes protecteurs choisis sur des groupes latéraux amino primaires de manière à assurer leur clivage éventuel sélectif; b) ces groupes protecteurs sont clivés, produisant au moins un groupe amino primaire libre; c) un dérivé ester à activité haptène est couplé sur au moins un groupe amino primaire libre du peptide; et d) le cas échéant, les groupes protecteurs restants sont clivés. L'haptène est choisi dans un groupe comprenant les stérines, les acides galliques, les hormones sexuelles, les corticoïdes, les cardénolides, les glycosides cardénolidiques, les bufadiénolides, les sapogénines stéroïdiques et les alcaloïdes stéroïdiques.
Also published as
FI961350
NO19961162
NZ291155
Latest bibliographic data on file with the International Bureau